What's the Matter with Clinical Trials?

Should clinical trials be re-tooled to better account for genetic diversity?

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

It is not well known that

It is not well known that most existing drugs only work for 25-65% of the population. We must obviously understand this phenomenon to correctly administer existing drugs AND develop new drugs. HOWEVER, assumption of differences in genes among individuals as the core biology dictating patient segregation is just that - an assumption with no supporting evidence. An almost wholesale reliance on gene-mutant selection of drug targets by pharma has proven that a sole focus on genes does not work.

We're rationalizing spending yet more billions of dollars on the assumption that biology is spelled G-E-N-E. A more holistic approach is required that unites genomics, epigenetics and new proteomics tools. Otherwise, we're simply the drunk looking for her keys under the street lamp.